International Peer-Reviewed Journal•Open Access•ISSN 2456-8880
irejournals@gmail.com•+91-7433024337

Home / Current Issue / Paper 1715278

1715278 Vol 9 · Issue 9 Download Paper

Theranostic Science Development with NMR/MRI/Radioligand Study; A Call for Collaborative Research in Target Delivery

Taiwo Temitope Philip

Subject area: Biological & Medical Sciences  ·  Area of research: Radiopharmacy and NMR Spectroscopy

DOI: 10.64388/IREV9I9-1715278

Abstract

There has been a wide spread in the cases of cancer in the recent decades with different types of cancers emerging every decade (Yang et al, 2018), management has evolved from great study with the discovery of chemotherapeutic agents. However, the adverse effects from these chemotherapeutic agents and chemotherapy (irradiation) have pointed the needs for more targeted drug discovery. In the last decades, development of targeted drug delivery via monoclonal antibodies and others has helped sharpen the management of cancer.

References

[1] Justine Deborne, Imad Benkhaled, Veronique Bouchaud, Noel Pinaud, Yannick Cremillieux (2024), Implantable theranostic device for in vivo real time NMR evaluation of drug impact in brain tumors, scientific reports 14, 4541 https://

[2] Kauppinen R.A & Peet A.C (2011), using magnetic resonance imaging and spectroscopy in cancer diagnosis and momitoring: Preclinical and clinical approaches. Cancer Biology & amp; Therapy, 12 (8) 665 -679, https://

[3] Luis O Gonzalez, Noemi Eiro, Maria Fraile, Nana Beridze, Andres Escaf, Safwan Escaf, Jesus Fernadez-Gomez, Francisco Vizoso, (2022) Prostate Cancer tumor stroma: responsibility in tumor biology, diagnosis and treatment, MDPI,

[4] Niall Crawley, Michael Thompson, Alexander Romaschin (2014), Theranostics in the growing field of personalized medicine: An analytical chemistry perspective, Analytical chemistry 86 (1), 130-160

[5] Yang Daniel X, Soulos Pamela R, Davis, Brigette MPH, Gross Cary P, James B (2018), Impact of widespread cervical cancer screening, numbers of cancers prevented and changes in race-specific incidence, American journal of clinical oncology,

[6] Ziwei Zhang, Feng-Lei Zhou, Gemma Louise Davies, (2022), Theranostics for MRI guided therapy, recents development, https://

How to cite this paper

Taiwo Temitope Philip "Theranostic Science Development with NMR/MRI/Radioligand Study; A Call for Collaborative Research in Target Delivery" Iconic Research And Engineering Journals Volume 9 Issue 9 2026 Page 3546-3548 https://doi.org/10.64388/IREV9I9-1715278
Taiwo Temitope Philip "Theranostic Science Development with NMR/MRI/Radioligand Study; A Call for Collaborative Research in Target Delivery" Iconic Research And Engineering Journals, vol. 9, no. 9, Mar. 2026, doi: https://doi.org/10.64388/IREV9I9-1715278
Taiwo Temitope Philip (2026). Theranostic Science Development with NMR/MRI/Radioligand Study; A Call for Collaborative Research in Target Delivery. Iconic Research And Engineering Journals, 9(9). doi: https://doi.org/10.64388/IREV9I9-1715278
Taiwo Temitope Philip "Theranostic Science Development with NMR/MRI/Radioligand Study; A Call for Collaborative Research in Target Delivery" Iconic Research And Engineering Journals, vol. 9, no. 9, Mar. 2026. Crossref, https://doi.org/10.64388/IREV9I9-1715278
@article{1715278,
      author = {Taiwo Temitope Philip},
      title = {Theranostic Science Development with NMR/MRI/Radioligand Study; A Call for Collaborative Research in Target Delivery},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {9},
      number = {9},
      pages = {3546-3548},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1715278.pdf},
      abstract = {There has been a wide spread in the cases of cancer in the recent decades with different types of cancers emerging every decade (Yang et al, 2018), management has evolved from great study with the discovery of chemotherapeutic agents. However, the adverse effects from these chemotherapeutic agents and chemotherapy (irradiation) have pointed the needs for more targeted drug discovery. In the last decades, development of targeted drug delivery via monoclonal antibodies and others has helped sharpen the management of cancer.},
      month = {March},
      doi = {https://doi.org/10.64388/IREV9I9-1715278}
  }